To facilitate Eurofarma’s manufacturing, the companies said technical transfer activities on-site development, and equipment installation will begin immediately.
According to the agreement, Eurofarma will receive the product from facilities in the U.S and the manufacturing of doses in Brazil will start in 2022.
At full operational capacity, annual production is expected to exceed 100 million doses. All doses will be distributed exclusively in Latin America. “Our new collaboration with Eurofarma expands our global supply chain network, helping us continue to provide fair and equitable access to our vaccine,” Albert Bourla, president and CEO of Pfizer, said.
To date, Pfizer and BioNTech have shipped more than 1.3 billion doses of their vaccine against COVID-19 to more than 120 countries and territories in all regions of the the world.